2 396

Cited 46 times in

Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells

DC Field Value Language
dc.contributor.author김주항-
dc.contributor.author손주혁-
dc.contributor.author양재문-
dc.contributor.author윤채옥-
dc.contributor.author허용민-
dc.date.accessioned2014-12-21T16:45:18Z-
dc.date.available2014-12-21T16:45:18Z-
dc.date.issued2007-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/96291-
dc.description.abstractTargeted adenoviral gene delivery using human epidermal growth factor receptor 2 (HER2/neu) is one of the promising strategies for enhancing the transduction efficacy of PEGylated adenovirus (PEG–ADV). The viral capsid of adenovirus carrying the green fluorescent protein (GFP) was conjugated with bifunctional polyethylene glycol (PEG). The surface of PEG–ADV was then further conjugated with anti-HER2/neu monoclonal antibody (MAb), Herceptin (Trastuzumab; HER) to grant HER2/neu over-expressed breast cancer cells specific targeting. The PEG–ADV and Herceptin immobilized PEG–ADV (HER–PEG–ADV) extents of retargeting were evaluated, as compared to those of naked ADV. In summary, HER–PEG–ADV exhibited more enhanced level of GFP expression than PEG–ADV did for MDA-MB-435 and MDA-MB-468 cells (a HER2/neu positive cell line), but not for a HER2/neu deficient U251N cells. PEGylated ADV significantly reduced innate immune response likewise, as judged from the amount of interleukin 6 released from macrophage cells. Consequently, this study suggests that HER–PEG–ADV conjugates enable ADV to become more potential therapeutic tools through overcoming the limitation of ADV against immune system and non-specificity.-
dc.description.statementOfResponsibilityopen-
dc.format.extent164~171-
dc.relation.isPartOfJOURNAL OF CONTROLLED RELEASE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenoviridae/genetics*-
dc.subject.MESHAdenoviridae/immunology-
dc.subject.MESHAnimals-
dc.subject.MESHAntibodies, Monoclonal/chemistry-
dc.subject.MESHAntibodies, Monoclonal/metabolism-
dc.subject.MESHAntibodies, Monoclonal/pharmacology*-
dc.subject.MESHAntibodies, Monoclonal/therapeutic use-
dc.subject.MESHAntibodies, Monoclonal, Humanized-
dc.subject.MESHAntineoplastic Agents/chemistry-
dc.subject.MESHAntineoplastic Agents/metabolism-
dc.subject.MESHAntineoplastic Agents/pharmacology*-
dc.subject.MESHAntineoplastic Agents/therapeutic use-
dc.subject.MESHBreast Neoplasms/genetics-
dc.subject.MESHBreast Neoplasms/metabolism-
dc.subject.MESHBreast Neoplasms/therapy*-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHChromatography, Liquid-
dc.subject.MESHFeasibility Studies-
dc.subject.MESHFemale-
dc.subject.MESHFlow Cytometry-
dc.subject.MESHGene Expression Regulation, Neoplastic-
dc.subject.MESHGenes, Reporter-
dc.subject.MESHGenetic Therapy/methods*-
dc.subject.MESHGenetic Vectors*/immunology-
dc.subject.MESHGreen Fluorescent Proteins/genetics-
dc.subject.MESHHumans-
dc.subject.MESHInterleukin-6/metabolism-
dc.subject.MESHLight-
dc.subject.MESHMacrophages/immunology-
dc.subject.MESHMacrophages/metabolism-
dc.subject.MESHMice-
dc.subject.MESHMicroscopy, Electron, Transmission-
dc.subject.MESHPolyethylene Glycols/chemistry*-
dc.subject.MESHReceptor, ErbB-2/genetics-
dc.subject.MESHReceptor, ErbB-2/metabolism-
dc.subject.MESHScattering, Radiation-
dc.subject.MESHTransduction, Genetic*-
dc.subject.MESHTrastuzumab-
dc.titleRetargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells-
dc.typeArticle-
dc.contributor.collegeResearcher Institutes (부설 연구소)-
dc.contributor.departmentYonsei Integrative Research Institute for Cerebral & Cardiovascular Disease (뇌심혈관질환융합연구사업단)-
dc.contributor.googleauthorYukyung Jung-
dc.contributor.googleauthorHyo-Jin Park-
dc.contributor.googleauthorSeungjoo Haam-
dc.contributor.googleauthorChae-Ok Yun-
dc.contributor.googleauthorYong-Min Huh-
dc.contributor.googleauthorJoo-Hang Kim-
dc.contributor.googleauthorJoo-Hyuk Sohn-
dc.contributor.googleauthorHyunju Ko-
dc.contributor.googleauthorJaemoon Yang-
dc.contributor.googleauthorWoochan Hyung-
dc.contributor.googleauthorJaewon Lee-
dc.contributor.googleauthorPyung-Hwan Kim-
dc.identifier.doi10.1016/j.jconrel.2007.08.002-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA01995-
dc.contributor.localIdA02614-
dc.contributor.localIdA04359-
dc.contributor.localIdA02315-
dc.relation.journalcodeJ01352-
dc.identifier.eissn1873-4995-
dc.identifier.pmid17854941-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0168365907004063-
dc.subject.keywordAdenovirus-
dc.subject.keywordPEG-
dc.subject.keywordHerceptin-
dc.subject.keywordTargeting-
dc.subject.keywordGene therapy-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameYang, Jae Moon-
dc.contributor.alternativeNameYun, Chae Ok-
dc.contributor.alternativeNameHuh, Yong Min-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorYun, Chae Ok-
dc.contributor.affiliatedAuthorHuh, Yong Min-
dc.contributor.affiliatedAuthorYang, Jae Moon-
dc.rights.accessRightsnot free-
dc.citation.volume123-
dc.citation.number2-
dc.citation.startPage164-
dc.citation.endPage171-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, Vol.123(2) : 164-171, 2007-
dc.identifier.rimsid35036-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Research Institute (부설연구소) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.